Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Triveni Kothapalli

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

Pipette,Adding,Fluid,To,One,Of,Several,Test,Tubes,,Medical

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

The acquisition adds Polynoma's lead candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine being developed for the adjuvant treatment of stage IIB and IIC melanoma, to TransCode's development pipeline.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.